Stephen Baxter, an analyst from Wells Fargo, maintained the Buy rating on Elevance Health. The associated price target was lowered to $400.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stephen Baxter has given his Buy rating due to a combination of factors that, despite some uncertainties, present a compelling valuation for Elevance Health. The company has reiterated its full-year EPS guidance, suggesting confidence in offsetting higher medical costs with lower general and administrative expenses in the second half of 2025.
Despite the lowered price target to $400, reflecting uncertainties in Exchange, Medicaid, and Medicare Advantage margins, the valuation remains attractive. The adjustments in expectations for exchange and Medicaid margins have been largely acknowledged, and the potential for improvement in 2026 adds to the positive outlook. Baxter’s analysis indicates that while there are risks, the current valuation offers an opportunity once the estimates stabilize.
In another report released yesterday, UBS also maintained a Buy rating on the stock with a $484.00 price target.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ELV in relation to earlier this year.